



SEC 17 / 2026-27

23rd May 2026

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort,
Mumbai 400 001
Maharashtra, India
Scrip Code: **500114**

National Stock Exchange of India Ltd
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: **TITAN**

Dear Sir,

Sub: Newspaper publication for Postal Ballot Notice

Further to our letter no. SEC 16 / 2026-27 dated 22nd May 2026 and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ('Listing Regulations') as amended from time to time, please find enclosed copies of the Newspaper Advertisements published in Business Standard (English version) and Dinamalar (Tamil version) on 23rd May 2026 with regard to Postal Ballot Notice and e-voting intimation to Members.

This is for your information and records.

Thank you.

Yours truly,
For TITAN COMPANY LIMITED

Dinesh Shetty
General Counsel & Company Secretary

Encl. As stated

Titan Company Limited

`INTEGRITY` #193 Veerasandra Electronics City P.O. Off Hosur Main Road, Bangalore 560100 India. Tel: 9180 6704 7000 Fax: 9180 6704 6262
Registered Office 3, Sipcot Industrial Complex Hosur 635 126 TN India. Tel-91 4344 664 199 Fax 91 4344 276037, CIN: L74999TZ1984PLC001456

www.titancompany.in

A TATA Enterprise

High-value clinical research marks gradual shift to India

ANJALI SINGH
Mumbai, 22 May

India is increasingly evolving from a low-cost outsourcing destination into a strategic innovation and decision-making hub for global pharmaceutical companies, as multinational firms shift more high-value clinical research and development functions to the country, according to Parexel, a global clinical research and drug development services company.

Speaking to *Business Standard*, Sanjay Vyas, president and managing director of Parexel, said India now accounts for more than 6,000 employees, or around 25-30 per cent of the company's global workforce of over 24,000 people. Indian operations have expanded beyond traditional support functions to handle a broad range of core clinical research activities, including clinical operations, pharmacovigilance, regulatory affairs, biostatistics,

Gaining ground

- Multinational pharma firms have established large capability hubs in India
- Large disease burden, expanding hospital infra, and growing health care awareness drawing global clinical studies
- India's maturing regulatory environment, clinical trial ecosystem attracting global pharma



supply chain management and AI-enabled automation.

"India is no longer just about cost arbitrage. The discussion is increasingly shifting towards value arbitrage," Vyas said, adding that global pharmaceutical companies are leveraging India for innovation, technology development and scalable clinical trial operations.

Several multinational pharma companies have established large capability hubs in

India, with critical functions and decision-making responsibilities gradually moving from the US and Europe to Indian centres, he said. Parexel India operates almost like a full-fledged standalone clinical research organisation, supporting both multinational pharma companies and Indian biotech firms, Vyas added.

India is also emerging as an important market for biotech and biosimilar companies, particularly in areas such as oncol-

ogy, respiratory therapies, immunology, as well as cell and gene therapy, he said.

As investments in biotechnology and advanced therapies increase, Parexel expects its India workforce to grow further over the next few years.

"I won't be surprised if we are talking about 8,000 employees in India over the next three years," Vyas said.

The shift comes as India's regulatory environment and clinical trial ecosystem continue to mature. Vyas said India's clinical trial regulations are increasingly aligning with standards followed by the US Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the European Medicines Agency (EMA).

India is also witnessing growing interest in decentralised and digital clinical trials, particularly around automation led by artificial intelligence, real-time data

processing, and pharmacovigilance. Vyas said the increasing complexity and scale of clinical trials are pushing companies to adopt technology-driven workflows to accelerate drug development timelines and improve regulatory submissions.

Parexel recently acquired Vitara, which focuses on AI-driven automation for pharma covigilance and safety reporting. It has also partnered global firms such as WeveBio and Paradigm to improve investigational new drug submissions and patient recruitment using AI-enabled systems.

According to Vyas, India's large disease burden, expanding hospital infrastructure, and growing health care awareness are making the country increasingly important for global clinical studies. However, he said India still accounts for only around 3 per cent of global clinical trial patient participation despite its population size, highlighting the sector's untapped potential.

Top listed real-estate firms ended FY26 on stable footing

PRACHI PISAL
Mumbai, 22 May

India's listed real-estate developers closed the fourth quarter of 2025-26 (Q4FY26) on a stable footing, outperforming the wider market, aided by strong execution and rising premium as well as luxury housing demand, even as the broader housing market entered a phase of moderation after the sharp post-pandemic upcycle.

Pre-sales growth for leading developers was largely in the mid-teen range, supported by calibrated launches and disciplined supply additions. Analysts said developers also turned increasingly selective on launches, carefully assessing demand signals and avoiding inventory build-up. Management teams are cautiously optimistic for Q1FY27 and more confident on the first half (H1) of FY27. A lot, however, will depend on the normalisation of the geopolitical situation, said Akshay Shetty, research analyst, Mirae Asset ShareKhan.

DLF India, Godrej Properties, and Prestige Group achieved their respective FY26 sales guidance, while Lodha group missed its pre-sales guidance for the year, as March saw select deferral of sales due to the Iran war, leading to pre-sales being ₹470 crore below the FY26 guidance (₹21,000 crore). The company's pre-sales for the year stood at ₹20,530 crore, up 16 per cent Y-o-Y.

Godrej had guided ₹32,500 crore of pre-sales for FY26 and achieved 105 per cent of it, with bookings worth ₹34,171 crore, up 16 per cent Y-o-Y. Prestige's FY26 sales surpassed guidance, rising 76 per cent Y-o-Y to highest-ever levels in its history at ₹30,024.5 crore. DLF's FY26 bookings were in line with its guidance at ₹20,143 crore.

Karan Khanna, lead analyst for real estate, Ambit Capital, said consolidation remained the defining trend, with customers increasingly preferring

grade-A developers with strong execution track records. He noted that top developers continued to witness significantly better launch absorption compared to the rest of the market. Markets such as Bengaluru, Hyderabad, and Delhi-NCR remained relatively strong, driven by end-user demand, GCC (global capability center) expansion, and infrastructure-led absorption.

Analysts said earnings were supported by premiumisation, stronger realisations, and pricing power in select micro-markets, although developers are now balancing margin preservation with sustaining sales velocity. Price hikes have become more calibrated compared to the aggressive increases seen over the past

two years. In Q4FY26, housing sales across top Indian cities declined 2.2 per cent Y-o-Y, according to property consultancy PropTiger.

Anuj Puri, chairman, Anarock group, said the quarter did not point to a generalised slowdown. Instead there was a deeper consolidation in favour of large developers with healthy balance sheets, execution discipline, and strong brand equity.

However, according to Vijay Agarwal, sector lead, infrastructure, Equirus Capital, the underlying demand environment warrants closer monitoring, as the sector settles into a mature, moderated rhythm from its previously elevated pace.

Real estate companies saw temporary disruptions amid geopolitical uncertainty in West Asia during late March, particularly impacting NRI, or non-resident Indian-led luxury demand. Analysts, however, said the impact appeared sentiment-driven and short-lived and did not indicate a broader demand collapse.

More on business-standard.com

Snabbit announces salon-at-home services

Snabbit, the quick home services platform, said it has entered the beauty services category with an instant salon-at-home offering that brings trained beauty professionals to customers' homes in minutes. "Beauty services is a high-frequency category with a large addressable market that overlaps perfectly with the core category we have built," said Aayush Agarwal, founder and chief executive officer, Snabbit. "Consumers today expect convenience everywhere, but availing beauty services still

involves long waiting periods. We see an opportunity to fundamentally rethink the experience through speed, reliability and hyperlocal fulfilment."

While categories like food delivery, groceries and home services have rapidly shifted toward instant fulfilment, beauty services have remained largely appointment-led, often requiring consumers to book hours or days in advance. Snabbit is aiming to change that by enabling high-frequency beauty services on demand. PEERZADA ABRAR

— Advertorial

IPL BIOLOGICALS INAUGURATES STATE-OF-THE-ART cGMP-COMPLIANT BIOLOGICAL MANUFACTURING FACILITY TO TRANSFORM SUSTAINABLE FARMING IN INDIA

IPL Biologicals Ltd. inaugurated its state-of-the-art, cGMP-compliant Biological Manufacturing Facility in Vadodra, Gujarat. This landmark investment marks a decisive step forward in accelerating Prime Minister Narendra Modi's national appeal to reduce chemical fertilizer usage by up to 50% and transition toward safer, sustainable, and self-reliant farming practices.



The inauguration ceremony was attended by the company's brand ambassador, cricket icon Yuvraj Singh, alongside Scientist, policy makers as well as key distributors and progressive farmers. The facility represents a major scale-up in India's indigenous agri-biological ecosystem, directly empowering farmers to restore soil health while maintaining crop productivity.

Spread across 12 acres with a built-up area of 2 lakh square feet, the facility increases IPL Biologicals' total production capacity to 70000 L per day. Engineered for the future of biological manufacturing, the plant features a fully automated production line with automatic harvesting and transfer systems, enabling near-zero human intervention. The facility operates with a Zero-Liquid-Discharge (ZLD) system that recycles all wastewater and generates 500 kW of captive solar power, reflecting IPL Biologicals' deep commitment to responsible and sustainable manufacturing.

The plant is cGMP-compliant, meets OHSAS and ISO 9001:2015 standards, is SCADA-controlled for real-time process monitoring, and holds IMO, Incocert, and OMRI organic certifications, enabling its products to serve discerning markets across the globe.

The facility is dedicated to producing next-generation biofertilizers, biopesticides, and crop health products, placing advanced agri-input solutions in the hands of India's Annadatas. New biological manufacturing plants in India boost domestic production capacity, ensuring farmers receive high-quality biofertilizers and biopesticides. By enabling farmers to replace synthetic chemicals, these facilities drastically reduce the national fertilizer subsidy burden and reliance on imports. This shift simultaneously restores soil health, improves produce quality, and protects human health.

The expansion of domestic biologicals directly transforms India's agricultural and economic landscape through several key mechanisms:

● **Environmental and Soil Health:** Integrating microbial formulations and bio-

fertilizers replaces depleted soil nutrients naturally. This avoids the long-term soil acidification caused by continuous synthetic fertilizer use, promoting cumulative soil fertility season after season.

● **Reduced Subsidy Burden:** By promoting self-sustaining microbial nutrient conversion and crop protection, the agricultural sector requires fewer heavily subsidized chemical inputs. This takes immense financial strain off the national exchequer.

● **Forex Reserve Improvement:** By shifting to locally produced biologicals, the nation reduces its reliance on imported chemical inputs, protecting the economy from global price shocks and preserving valuable foreign exchange reserves.

● **Human Health & Produce Quality:** Transitioning away from harsh chemical pesticides and fertilizers limits toxic runoff into water supplies and decreases dietary chemical residue, leading to safer, higher-quality agricultural outputs for consumers.

Leadership and Stakeholder Commentary
"Prime Minister Modi's call for up to a 50% reduction in chemical fertilizer usage is a civilizational imperative for our soil, our health, and our nation. This facility is IPL Biologicals' direct response to that call. We are scaling our three decades of microbial innovation to provide India's Annadatas with advanced, eco-friendly biological solutions that make sustainable agriculture a practical, profitable, and everyday reality."

— Harsh Vardhan Bhagchandka, President, IPL Biologicals Ltd.

"To win big, you need the right strategy, the right timing, and the right intent. PM Modi has given Indian agriculture a clear goal to cut chemical fertilizer usage by half, and IPL Biologicals is delivering the winning toolkit. Our farmers are the true champions, and this world-class facility ensures they have access to the best bio-inputs to protect their land and secure their yields for

future generations."
— Yuvraj Singh, Brand Ambassador, IPL Biologicals Ltd.

"Reducing chemical inputs by 50% is not just an environmental goal; it is an economic necessity for smallholder farmers. When we replace heavy chemical loads with high-efficiency biofertilizers, we significantly reduce input costs while preserving soil fertility. This plant brings world-class scientific solutions directly to the grassroots level."

IPL is committing to aggressive investments to expand its biological production capacity, expecting the government to implement industry-friendly policies. Achieving this agricultural transition requires policy frameworks that actively motivate farmers to adopt biologicals and reduce their reliance on chemical fertilizers. Increased domestic production, paired with targeted government incentives, creates a powerful cascading effect across India's economy and environment — Mahesh Bhagchandka, CMD, IPL Biologicals Ltd.

With over 30 years of expertise in microbial-based products, IPL Biologicals continues to empower more than 45 million farmers across 27+ countries through a network of over 8,000 distributors. The company offers a portfolio of 90+ products developed by a team of more than 50 scientists at its Technology and Innovation Centre. IPL Biologicals currently holds 19 patents, with 37 additional patents in process. This new facility marks the next bold chapter in the company's journey toward advancing sustainable agriculture at scale.

About IPL Biologicals Ltd.
IPL Biologicals Ltd. is a leading provider of biological solutions for sustainable agriculture, offering one of the industry's widest portfolios of biofertilizers and biopesticides. Its portfolio of 90+ products supports disease and pest management, plant nutrition and health management, and soil health enhancement. The company's Technology and Innovation Centre focuses on microbial product development through advanced high-tech microbial technologies, driven by a multidisciplinary team of more than 50 scientists. IPL Biologicals operates a state-of-the-art manufacturing facility specializing in microbial-based products across multiple user-friendly formulations, produced under advanced aseptic manufacturing conditions to ensure superior quality and efficacy.

Indus Fila Limited

Registered Office: 243/1 to 358/3, Thoramavu and Immavu Village, Thandya Industrial Area, K S Hundi, Nanjangud Taluk, Mysore 571302
CIN: L17121KA1999PLC025320 Email: accounts@indusfila.com

Extract of Audited Standalone Financials Results for the quarter and year ended 31st March, 2026
(All amounts in lakhs of INR, unless otherwise stated)

Sl No	Particulars	Quarter Ended 31.03.2026	Quarter Ended 31.03.2025	Year Ended 31.03.2026	Year Ended 31.03.2025
1	Total Income from Operations	--	5.00	--	16.00
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items #)	(56.77)	(59.82)	(255.27)	(226.51)
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items #)	(56.77)	(59.82)	(255.27)	(226.51)
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items #)	(57.48)	(62.19)	(257.40)	(228.88)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(57.48)	(62.19)	(257.40)	(228.88)
6	Equity Share Capital	510.84	510.84	510.84	510.84
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	(1838.45)	(1581.06)	(1838.45)	(1581.06)
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations) -	(1.13)	(1.22)	(5.04)	(4.48)
	1. Basic:				
	2. Diluted:				

Notes
1. The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Financial Results are available on the websites of the Stock Exchange(s).
2. The impact on net profit / loss, total comprehensive income or any other relevant financial item(s) due to change(s) in accounting policies shall be disclosed by means of a footnote.
3. # - Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

For and on behalf of the Board of Directors
Indus Fila Limited
Sd/-
ABHAY MANDHANA
Director
DIN: 07695839

Date: 21-05-2026
Place: Mysuru

TITAN COMPANY LIMITED

A TATA Enterprise
CIN: L74999T21984PLC001456
Registered Office: 3, SIPCOT Industrial Complex, Hosur - 635 126, Tamil Nadu.
Corporate Office: 'INTEGRITY', No.193, Veerasandra, Electronics City P.O., Off Hosur Main Road, Bengaluru - 560 100, Karnataka
Tel: +91-80-6704 7000 E-mail: investor@titan.co.in Website: www.titancompany.in

POSTAL BALLOT NOTICE AND E-VOTING INTIMATION TO MEMBERS

Notice is hereby given that Titan Company Limited ("Company") is seeking approval of its Members on the following Special Resolution through Postal Ballot by voting only through electronic means (remote e-voting):

Sl. No.	Description of Resolution	Type of Resolution
1.	Appointment of Mr. Srinivasan Varadarajan (DIN: 00033882) as an Independent Director	Special

The Postal Ballot Notice ("Notice") is available on the website of the Company at www.titancompany.in and on the website of National Securities Depository Limited ("NSDL") at www.evoting.nsdl.com. Additionally, the Notice will also be available and may be accessed from the relevant section of the websites of the Stock Exchanges i.e., BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") at www.bseindia.com and www.nseindia.com, respectively.

Pursuant to Section 110 read with Section 108 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act"), (including any statutory modifications or re-enactments thereof for the time being in force), read with Rules 20 and 22 of Companies (Management and Administration) Rules, 2014, ("the Rules"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), Secretarial Standard on General Meetings issued by The Institute of Company Secretaries of India ("SS-2"), each as amended, and in accordance with the requirements prescribed by the Ministry of Corporate Affairs ("MCA") for holding general meeting/conducting postal ballot process through e-voting vide various MCA Circulars, the Company is providing remote e-voting facility to all its Members to enable them to cast their votes electronically on the resolution set forth in the Notice instead of submitting the physical Postal Ballot form. The Company has, on Friday, 22nd May 2026, completed dispatch of Notice dated 21st May 2026, seeking approval of the Members of the Company by e-mail only to the Members whose name appear in the Register of Members/List of Beneficial Owners as received from NSDL and Central Depository Services (India) Limited ("CDSL") and whose e-mail address are available with the Company as on Friday, 15th May 2026 ("Cut-off date"). The voting rights shall also be reckoned on the paid-up value of shares registered in the name(s) of the Members as on the Cut-off date. Accordingly, physical copy of the Notice along with the Postal Ballot forms and pre-paid business envelope have not been sent to the Members for this Postal Ballot.

The Company has engaged the services of NSDL for facilitating remote e-voting to enable the Members to cast their votes electronically and in a secure manner. The remote e-voting period shall commence on **Monday, 25th May 2026 at 9:00 a.m. (IST)** and end on **Tuesday, 23rd June 2026 at 5:00 p.m. (IST)**. The remote e-voting facility shall be disabled by NSDL immediately thereafter and will not be allowed beyond the said date and time. Members are requested to record their Assent (FOR) or Dissent (AGAINST) through the remote e-voting process not later than 5:00 p.m. IST on Tuesday, 23rd June 2026. Members of the Company holding shares either in physical or in electronic form as on the Cut-off date shall cast their vote electronically. Once the vote on the resolutions is cast by the Member, the Member shall not be allowed to change it subsequently.

Eligible Members whose e-mail address is not registered/updated with the Company/Depositories' RTA may register/update their e-mail addresses on or before **05:00 p.m. (IST) on Monday, 1st June 2026**, to receive a copy of the Notice. The procedure to register the e-mail address with the RTA and the procedure of remote e-voting is provided in the Notice.

The Board of Directors has appointed Mr. V. Sreedharan (FCS No. 2347; CP No. 833) or in his absence Mr. Pradeep B. Kulkarni (FCS 7260; CP 7835) of M/s. V. Sreedharan & Associates, Practicing Company Secretaries, as the Scrutinizer to scrutinize the postal ballot process in a fair and transparent manner.

The results of the e-voting conducted through Postal Ballot (through the remote e-voting process) along with the Scrutinizer's Report will be announced on or before 5.00 p.m. (I.S.T) on Thursday, 25th June 2026. The same will be displayed on the website of the Company at www.titancompany.in, the website of NSDL at <http://www.evoting.nsdl.com/> and shall also be communicated to BSE and NSE where the Company's Equity Shares are listed and be made available on their respective websites viz., www.bseindia.com and www.nseindia.com. Additionally, the Results will also be placed on the notice board at the Registered Office of the Company.

In case of any queries, you may refer to the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 022-48867000 or send a request to evoting@nsdl.com.

Members are requested to carefully read all the notes set out in the Notice and in particular, the manner of casting vote through remote e-voting.

By Order of the Board of Directors
For Titan Company Limited
Sd/-
Dinesh Shetty
General Counsel & Company Secretary
FCS No.: 3879

Place: Bengaluru
Date: 22nd May 2026

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)
Regd. Office: Plot No.2, Maithrivi, Ameerpet, Hyderabad - 500 038, Telangana, India.
Tel: +91 40 23736370 Fax: +91 40 23747340 Email: info@aurobindo.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR YEAR ENDED MARCH 31, 2026 AND UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026
(All amounts are in ₹ in millions, unless otherwise stated)

Sr. No.	Particulars	Quarter Ended		Year Ended
		31.03.2026	31.03.2026	31.03.2025
		Unaudited	Audited	Unaudited
1	Total income from operations (net)	88,533.4	3,36,530.8	83,821.2
2	Profit before exceptional items and tax	12,906.1	51,771.8	13,350.9
3	Profit before tax (after exceptional items)	12,906.1	51,118.5	13,350.9
4	Profit after tax	9,208.4	35,029.7	9,028.3
5	Total Comprehensive income for the period [Comprising Profit for the period (after tax) and Other Comprehensive income (after tax)]	17,114.0	54,681.7	10,424.9
6	Paid-up equity Share Capital (face value of ₹ 1/- each)	580.8	580.8	580.8
7	Other equity (excluding Revaluation Reserve) as shown in the unaudited financial results	-	-	-
8	Other equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	As on March 31, 2025 325,952.4		
9	Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Annualised)	(Not annualised)
	(a) Basic (in ₹)	15.86	60.34	15.56
	(b) Diluted (in ₹)	15.86	60.34	15.56

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR YEAR ENDED MARCH 31, 2026 AND UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026
(All amounts are in ₹ in millions, unless otherwise stated)

Sr. No.	Particulars	Quarter Ended		Year Ended
		31.03.2026	31.03.2026	31.03.2025
		Unaudited	Audited	Unaudited
1	Total income from operations (net)	27,865.5	1,11,717.2	27,319.9
2	Profit before exceptional items and tax	8,763.1	31,809.6	5,555.2
3	Profit before tax (after exceptional items)	8,763.1	31,635.8	5,555.2
4	Profit after tax	6,922.3	24,148.0	4,081.7
5	Total Comprehensive income for the period [Comprising Profit for the period (after tax) and Other Comprehensive income (after tax)]	6,958.5	24,158.8	4,072.6
6	Paid-up equity Share Capital (face value of ₹ 1/- each)	580.8	580.8	580.8
7	Other equity (excluding Revaluation Reserve) as shown in the unaudited financial results	-	-	-
8	Other equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	As on March 31, 2025 204,760.3		
9	Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Annualised)	(Not annualised)
	(a) Basic (in ₹)	11.92	41.58	7.03
	(b) Diluted (in ₹)	11.92	41.58	7.03

Note: The above is an extract of the detailed format of Quarter and Year ended Financial Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange web sites viz. www.bseindia.com, www.nseindia.com and on the Company's web site viz. www.aurobindo.com and can also be accessed through the QR code given below.

By Order of the Board
Aurobindo Pharma Limited
Sd/-
K. Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195

Place: Hyderabad
Date : May 21, 2026

www.aurobindo.com

